2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Supportive Care, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Adverse Events, Artificial Intelligence (AI), Natural Language Processing, Biological Processes, Microbiome, Clinical Practice (Health Services and Quality), Practice Models, Quality Improvement, Quality of Care, Diseases, Bone Marrow Failure Syndromes, Aplastic Anemia, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Immunology, GVHD, Infectious Diseases, Viral, Bacterial, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, MPN, Clinical Research, Clinical Trials, Real-World Evidence, Registries, Study Population, Human, Adult
PAPER

2455 Alemtuzumab versus antithymocyte globulin for conditioning in allogeneic stem cell transplantation for acquired aplastic anemia: A retrospective SFGM-TC registry study

Jonathan Bordat, MD, Jacques-Emmanuel Galimard2, Ibrahim Yakoub-Agha, MD, PhD3, Jean Baptiste Mear, MD4, Anne Huynh, MD5, Johan A. Maertens, MD6, Raynier Devillier, PhD7, Hélène Labussière-Wallet, MD8, Mustafa Alani9, Jean Valere Malfuson10, Philippe Lewalle, MD, PhD11, Marie-Thérèse Rubio12, Gaëlle Guillerm13, Patrice Chevallier, MD, PhD14, Karin Bilger15, Ludovic Gabellier, MD16, Claude-Éric Bulabois17, Edouard Forcade, MD, PhD18, Florent Malard, MD, PhD19, Xavier Poire, MD, PhD20, Sylvain Chantepie, MD21, Sandrine Visentin22, Marie Ouachee Chardin, MD23, Amandine Charbonnier24, Felipe Suarez, MD, PhD25, Benedicte Bruno26, Angoso Marie27, Stephanie Nguyen Quoc28, Regis Peffault De Latour, MD, PhD29, Flore Sicre-de-Fontbrune, MD30
1 Saint-Louis Hospital, APHP, PARIS, France
2 EBMT Paris Study Unit, Sorbonne University, Saint-Antoine Hospital, AP-HP, INSERM UMRs 938, Paris, France
3 Lille University Hospital, Lille, France
4 Rennes University Hospital, Rennes, France
5 CHU/Department of Hematology, IUCT Oncopole, Toulouse, France, Toulouse, France
6 University Hospital Gasthuisberg, Leuven, Belgium
7 Institut Paoli-Calmettes, Aix Marseille Universit, Marseille, France
8 Lyon Sud Hospital, Hospices Civils de Lyon, Lyon, France
9 Department of Hematology, Rouen University Hospital, Rouen, France
10 Hôpital d'Instruction des Armées Percy, Percy, France
11 Department of Hematology, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium
12 Nancy University Hospital, Vandœuvre-lès-Nancy, Nancy, France
13 Brest University Hospital, Brest, France
14 Nantes University Hospital, Nantes, France
15 Strasbourg University Hospital, Strasbourg, France
16 Hôpital Saint Eloi, Montpellier, France
17 Department of Hematology, Grenoble University Hospital, Grenoble, France
18 Haut-Lévêque Hospital, Bordeaux University Hospital, Bordeaux, France
19 Hôpital Saint-Antoine, AP-HP, Paris, France
20 Institut Roi Albert II, Cliniques Universitaires Saint-Luc, Brussels, Belgium
21 Department of Clinical Hematology, Caen University Hospital, Caen, France
22 Immunology and Oncology, Aix-Marseille University, APHM, La Timone Children's Hospital, Marseille, France
23 Institute of Pediatric Oncology and Hematology, Lyon, France
24 CHU AMIENS, AMIENS, France
25 Hôpital Necker, APHP, Paris, France
26 Lille University Hospital, Lille, France
27 University Hospital of Bordeaux, Bordeaux, France
28 Hôpital Pitié-Salpêtrière, Paris, France
29 Saint-Louis Hospital, APHP, PARIS, France
30 Saint-Louis Hospital, APHP, PARIS, France

Introduction:

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment for aplastic anemia (AA). In vivo T-cell depletion has been associated with reduced incidences of graft-versus-host disease (GvHD) and graft failure in large retrospective studies, translating into better overall survival. However, the optimal agent for T-cell depletion, antithymocyte globulin (ATG) versus alemtuzumab, remains uncertain, given the absence of prospective comparative trials.

 

Methods:

We conducted a matched retrospective analysis using data from the French Bone Marrow Transplantation Society (SFGM-TC) registry, including patients aged >15 years who underwent a first allo-HSCT for acquired AA between 2015 and 2023. Only patients receiving in vivo T-cell depletion with ATG or alemtuzumab were included.

Because of the restricted access to alemtuzumab in France patients were selected according to its compassionate-use indication: patients aged over 40 years transplanted with a matched related donor (MRD), or patients transplanted with a matched/mismatched unrelated donor (MUD/MMUD) regardless of age. Given the small number of alemtuzumab patients, we used inverse-probability-of-treatment weighting (IPTW). The following covariates were included: year of transplant, time from diagnosis to transplant, donor type, recipient age, recipient CMV status, KPS, and HCT-CI score.

 

Results:

Patient characteristics before weighting:

Before weighting, 149 patients were included (44 alemtuzumab, 105 ATG). Groups were balanced for recipient age (median 41.0 vs. 38.4 years, p=0.795), sex, HCT-CI (score 0 in 56.8% vs. 57.1%, p=0.861), and donor type (MUD 65.9% vs. 68.6%; MRD 25.0% vs. 22.9%; MMUD 9.1% vs. 8.6%, p=0.950). Alemtuzumab patients were transplanted more recently (median 2020 vs. 2019, p=0.036), more often after failure of first-line immunosuppressive treatment with cyclosporine plus ATG (79.5% vs. 60.0%, p=0.035), and after a longer interval from diagnosis (median 19.2 vs. 12.1 months, p=0.036). Reflecting the alemtuzumab indication and French guidelines, several transplant-related characteristics differed: less frequent total body irradiation (4.5% vs. 53.3%, p<0.001), more frequent cyclophosphamide-fludarabine conditioning (97.7% vs. 77.1%, p=0.005), predominant cyclosporine-alone GVHD prophylaxis (81.8% vs. cyclosporine-methotrexate 83.8%, p<0.001), and more frequent peripheral blood stem cells (50.0% vs. 24.8%, p=0.005).

 

Outcomes after the propensity score:

After IPTW weighting (effective sample size : 37 alemtuzumab and 97 ATG), all model covariates were balanced (standardized mean difference <0.1), with no extreme weights. As expected, variables tied to the two strategies and deliberately excluded from the model remained imbalanced: total body irradiation (4.1% vs. 56%), CY-FLU conditioning (97% vs. 77%), GVHD prophylaxis, and graft source (PBSCs 44% vs. 24%).

Median follow-up was 26.4 and 39.8 months, respectively. At two years, overall survival was comparable between alemtuzumab and ATG (85.4% vs. 80.2%, HR 0.59 [0.23–1.50], p=0.266), as were graft-failure-free, severe-GVHD-free, relapse-free survival (GF-GRFS: 78.7% vs. 70.8%, HR 0.63 [0.29–1.38], p=0.250), non-relapse mortality (7.2% vs. 14.2%, HR 0.44 [0.12–1.65], p=0.222) and the incidence of relapse/graft failure (14.1% vs. 7.5%, HR 1.75 [0.63–4.9], p=0.285). The 180-day incidence of grade I-IV acute GVHD was markedly lower with alemtuzumab (2.8% vs. 29.2%, HR 0.08 [0.02–0.34], p<0.001), as was grade II-IV (1.4% vs. 13.6%, HR 0.09 [0.01–0.71], p=0.022). Grade III–IV aGVHD was rare in both groups (0.0% vs. 1.9%). By contrast, two-year chronic GVHD (all grades) was similar (18.7% vs. 18.9%, HR 0.78 [0.32–1.87], p=0.572), with no moderate-to-severe chronic GVHD in the alemtuzumab group (0.0% vs. 5.5%). Neutrophil engraftment was comparable (median 20 vs. 22 days, p=0.200), whereas platelet engraftment was faster with alemtuzumab (median 15 vs. 22 days, p=0.013).

 

Conclusion:

In this propensity-score weighted, single-center analysis, in vivo T-cell depletion with alemtuzumab reduced grade I-IV and II-IV acute GVHD compared with ATG, without a demonstrable improvement in chronic GVHD, GF-GRFS, or overall survival. These findings support alemtuzumab as an effective alternative to ATG, particularly valuable when TBI or a bone marrow graft is unavailable.

Jonathan Bordat, MD: No relevant conflicts of interest to declare.